Perioperative Outcomes of a Hydrocortisone Protocol after Endonasal Surgery for Pituitary Adenoma Resection
- 27 September 2021
- journal article
- research article
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 83 (04) , 383-389
Abstract
Introduction In pituitary adenomas (PAs), the use of postoperative steroid supplementation remains controversial, as it reduces peritumoral edema and sinonasal complaints but disrupts the detection of adrenal insufficiency (AI). It is unclear whether postoperative cortisol supplementation has a measurable effect on improving outcomes in patients with pituitary adenoma undergoing endoscopic transsphenoidal surgery (ETS). The objective of the study was to evaluate a postoperative steroid treatment protocol on various surgical outcomes in patients with PA undergoing ETS.Methods A retrospective cohort study was performed for patients undergoing ETS from 2005 to 2020 for PA at a single tertiary academic center. Patients were divided into two groups: those managed by a routine postoperative glucocorticoid supplementation protocol (steroid protocol) and those who received supplementation based on postoperative cortisol laboratory assessment (steroid sparing protocol). Management was otherwise the same between groups. Evaluation of length of stay (LOS), sinonasal outcomes, 30-day readmission, and perioperative complications, including AI, were performed.Results Among 535 patients, 21% (n = 111) received postoperative steroids, while the remainder (n = 424) did not. There were no differences in mean LOS (3 vs. 3 days, p = 0.72), sinonasal complaints (27 vs. 19%, p = 0.12), 30-day readmission (5% vs. 5%, p = 0.44), and perioperative complications (5 vs. 5%, p = 0.79) between both the groups. A multivariate model supported that both groups were comparable in predicting LOS, 30-day readmission, and complications. No reduction in readmission for AI was seen.Conclusion Routine administration of postoperative glucocorticoids did not significantly improve patient outcomes in patients with PA who underwent ETS.Keywords
This publication has 37 references indexed in Scilit:
- Selective Use of Peri-Operative Steroids in Pituitary Tumor Surgery: Escape from DogmaFrontiers in Endocrinology, 2013
- Endocrine disorders: Causes of hyponatremia not to neglectAnnals of Medicine, 2010
- Endoscopic repair of high‐flow cranial base defects using a bilayer buttonThe Laryngoscope, 2010
- PITUITARY HORMONAL LOSS AND RECOVERY AFTER TRANSSPHENOIDAL ADENOMA REMOVALNeurosurgery, 2008
- Peri-operative glucocorticoid replacement therapy in transsphenoidal pituitary adenoma surgery: a prospective controlled studyActa Neurochirurgica, 2008
- Prospective evaluation of a protocol for reduced glucocorticoid replacement in transsphenoidal pituitary adenomectomy: prophylactic glucocorticoid replacement is seldom necessaryClinical Endocrinology, 2007
- Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor RegistryEuropean Journal of Endocrinology, 2007
- The prevalence of pituitary adenomasCancer, 2004
- Glucocorticoid replacement therapy: are patients over treated and does it matter?Clinical Endocrinology, 1997
- Perioperative Glucocorticoid Coverage A Reassessment 42 Years After Emergence of a ProblemAnnals of Surgery, 1994